Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Large Increase in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) was the target of a significant growth in short interest in the month of December. As of December 31st, there was short interest totalling 3,370,000 shares, a growth of 25.7% from the December 15th total of 2,680,000 shares. Based on an average trading volume of 286,800 shares, the days-to-cover ratio is presently 11.8 days. Currently, 7.4% of the company's shares are sold short.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. HC Wainwright reissued a "buy" rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Monday. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $25.60.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Rhumbline Advisers grew its stake in shares of Astria Therapeutics by 4.1% in the 2nd quarter. Rhumbline Advisers now owns 65,375 shares of the biotechnology company's stock worth $595,000 after acquiring an additional 2,556 shares in the last quarter. Quest Partners LLC grew its position in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock worth $29,000 after purchasing an additional 3,112 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Astria Therapeutics by 6.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 139,071 shares of the biotechnology company's stock valued at $1,266,000 after buying an additional 8,965 shares during the last quarter. Wellington Management Group LLP increased its stake in Astria Therapeutics by 8.7% in the 3rd quarter. Wellington Management Group LLP now owns 147,499 shares of the biotechnology company's stock valued at $1,624,000 after buying an additional 11,763 shares during the last quarter. Finally, PDT Partners LLC bought a new position in shares of Astria Therapeutics during the 3rd quarter worth approximately $140,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Stock Performance

NASDAQ:ATXS traded down $0.04 during mid-day trading on Thursday, hitting $7.75. 302,803 shares of the stock were exchanged, compared to its average volume of 336,190. The firm's 50-day simple moving average is $9.60 and its 200 day simple moving average is $10.65. The stock has a market capitalization of $437.36 million, a price-to-earnings ratio of -3.71 and a beta of 0.70. Astria Therapeutics has a fifty-two week low of $6.95 and a fifty-two week high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.